MAY 23, 2018 12:33 AM PDT

Drug Repurposing: Antimalarial Drug Treats Ovarian Cancer in Patient

WRITTEN BY: Nouran Amin

According to a recent published case report, a woman diagnosed with ovarian cancer was lead to recovery after being treated using a therapeutic for a different disease. The case report examined the relationship between the patient’s autoimmune disease and the treatment hoping it might have contributed to achieving such a "striking" response.

Researchers led by Professor of Medicine at NYU Langone's Perlmutter Cancer Center, Dr. Franco Muggia, described a case of a patient who received treatment for dermatomyositis, an autoimmune condition that leads muscle weakness and skin rashes. For this particular condition, the woman received treatment involving hydroxychloroquine and quinacrine, which are antimalarial drugs.However, the patient was later presented with an advanced and aggressive form of ovarian cancer.

Although there are effective treatments, ovarian cancer is known to recur within a median of 18 months to 2 years.

Dr. Muggia's patient surprised doctors with immediate and lasting response to the ovarian cancer treatment. Three years later, and the patient is ovarian-cancer free and dermatomyositis free. The follow-up results were also seen to have no evidence of the symptoms exhibited by these two diseases.

The particular antimalarial drugs, hydroxychloroquine and quinacrine, were previously studied to play a role in cancer treatment. They most likely appear to collaborate with cancer drugs to increase their efficacy.

These antimalarial drugs intended for dermatomyositis, that eventually treated the women’s ovarian cancer, have inspired the medical community to “repurpose” drugs; that is drugs developed to treat one condition were found to be useful for other conditions.

"This is an interesting example of serendipity—an incidental finding of a cancer patient responding strongly to a non-cancer drug used for the treatment of a co-morbid condition," explains Dr. Pan Pantziarka of The Anticancer Fund, Belgium, and one of the leaders of the Repurposing Drugs in Oncology (ReDO) Project. "It's important to publish such cases as they may provide early data for later preclinical and clinical investigation."

Dr. Muggia notes that conclusions from the case reports should not be drawn from the example of her patient. "However, the depth of the response of an aggressive high-grade serous ovarian cancer to the initial platinum-taxane doublet, after months of dermatomyositis and treatment with anti-malarial drugs, should encourage further inquiries into the role of autophagy, its subsequent inhibition, and immunity in enhancing responses to [platinum-based] chemotherapy. There is already strong evidence that anti-malarials such as hydroxychloroquine and chloroquine possess anticancer activity, as was summarized by the ReDO Project last year. If replicated, it would show yet again the therapeutic value still to be realized in so many of our existing non-cancer medicines."

Sources: Medical Xpress

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 08, 2018
Drug Discovery
AUG 08, 2018
Injection Improves Corneal Transplant Outcomes
The common form of tissue transplant is the corneal transplant. Corneal transplantation is performed to correct visual loss that has occurred when the corn...
AUG 14, 2018
Drug Discovery
AUG 14, 2018
Single Antiplatelet Drug Reduces Risk of Blood Clots
According to the current treatment protocol, patients that undergo minimally invasive aortic heart valve replacements will likely receive two antiplatelet...
SEP 20, 2018
Drug Discovery
SEP 20, 2018
Chemotherapeutic Drugs Battle Antimalarial Drug Resistance
According to the latest research published in the journal Nature Communications, researchers discovered that chemotherapeutic drugs can increase the effect...
DEC 09, 2018
Cannabis Sciences
DEC 09, 2018
Targeting CB1 Endocannabinoid Receptor: Specificity is the Key
The human endocannabinoid system (ECS) is one of the body's largest network of neurotransmitters, receptors, and neuromodulators. This system plays a r...
DEC 09, 2018
Drug Discovery
DEC 09, 2018
Insect Venom Can Someday Combat Antibiotic-Resistant Infections
Insect venom, such as those secreted by wasps and bees, are considered an insect’s immune system defense because of its richness in bacterial killing...
DEC 13, 2018
Drug Discovery
DEC 13, 2018
First Non-Opioid Drug?
In a study published in the medical journal—PAIN, a non-opioid drug compound discovered by researchers from the National Institute of Health (NIH)&md...
Loading Comments...